Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.
Also called NCT06921616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 396 participants
- Sponsor
- Yong Jiang
- Registry
-
NCT06921616
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06921616. Randomized; triple masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
- Acronym
- HEMS
- Condition
- Stroke
- Condition
- Intracerebral Hemorrhage Lobar
- Condition
- Methylprednisolone
- Condition
- Surgery
- Intervention (Procedure)
- Simple neuroendoscopic hematoma evacuation
- Intervention (Combination product)
- Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
- Lead sponsor
- Yong Jiang
Record details
- Record id
cardio:ct-nct06921616- Content hash
6fc750e45ab47626ea16595aae4690593a1e3986ecd945020aacee5ebc60f9e3